Eli Lilly (NYSE:LLY) reported positive topline Phase 3 results for EBGLYSS (lebrikizumab) in pediatric patients with moderate ...
Dermatologist Coast Dermatology The South Bay has counted on Coast Dermatology Medical Associates for over 35 years, since its founding by Dr. Mark ...
Spanish dermatology specialist Almirall has announced positive, top-line results from the pivotal Phase III ADorable-1 trial ...
HealthDay News — For children aged 2 to 5 years with atopic dermatitis (AD), roflumilast cream 0.05% has a favorable long-term safety profile and efficacy for up to 56 weeks, according to a study ...
On Friday, the U.S. Food and Drug Administration (FDA) approved Novartis AG’s NVS Cosentyx (secukinumab) for younger patients. The approval covers pediatric patients 12 years and older with moderate ...
Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
The Primary Healthcare Corporation (PHCC) has announced the operating schedule for its health centers during the Eid Al Fitr ...
US FDA approves Novartis Cosentyx for paediatric patients aged 12+ with moderate to severe hidradenitis suppurativa: Basel Monday, March 16, 2026, 14:00 Hrs [IST] Novartis announc ...
Hespress on MSN
2,575 beneficiaries of medical, surgical campaign by Mohammed V Foundation for Solidarity
A total of 2,575 people benefited from a local medical and surgical outreach campaign organized from March 13 to 15 by the Mohammed V Foundation for Solidarity in the municipality of Oued Amlil, in ...
Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results